Authors

Latest:

Dr. Trotman on BGB-3111 in Patients With Waldenstrom's Macroglobulinemia

Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.

Judy C. Boughey, MD

Latest:

Dr Boughey on Defining Optimal Candidates For Surgical De-Escalation in Breast Cancer

Judy C. Boughey, MD, discusses key characteristics that define the ideal population for surgical de-escalation among patients with breast cancer.

Judy C. Boughey, MD, FACS

Latest:

Minimizing Axillary Surgery for Patients With Node-Positive Breast Cancer

As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.

Juergen Wolf, MD

Latest:

Dr. Wolf on the Design of GEOMETRY mono-1 Trial in METex14-Mutated NSCLC

Jüergen Wolf, MD, discusses the design and rationale of the phase 2 GEOMETRY mono-1 study with capmatinib (Tabrecta) in METex14-mutated or high MET amplified, advanced non–small cell lung cancer.

Julia Fehniger, MD

Latest:

Dr. Fehniger on Expanding PARP Inhibitors to Other Gynecologic Cancers

Julia Fehniger, MD, shares her thoughts on the development of PARP inhibitors in ovarian cancer and expansion into other tumor types.

Julia K. Rotow, MD

Latest:

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.

Julia R. Mendoza-Perez, PhD

Latest:

Next Steps With Obesity-Related Genes in Patients With RCC

Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).

Julia R. White, MD

Latest:

Dr. White Discusses Exceptions in the Z11 Trial

Dr. Julia White from Community Memorial Hospital Discusses Exceptions in the Z11 Trial

Julia Rotow, MD

Latest:

Leveraging ctDNA Platforms in High-Risk Patients: Current Applications and Future Potential

Panelists discuss how they currently utilize emerging ctDNA platforms for high-risk patients and explore whether these advancements will soon become standard practice in clinical decision-making.

Julia von Tresckow, MD

Latest:

Dr. von Tresckow on "Sequential Triple-T" Trial in CLL

Julia von Tresckow, MD, specialist in oncology, University of Cologne, Department of Internal Medicine, and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, discusses the CLL2-BIG trial, which explored the combination of obinutuzumab (Gazyva) and ibrutinib (Imbruvica) for induction and maintenance treatment of physically fit and unfit patients with chronic lymphocytic leukemia (CLL). Patients with high tumor burden were given bendamustine as debulking.

Julia White, MD

Latest:

Dr. White on Research With Regional Nodal Irradiation in Node-Positive Breast Cancer

Julia R. White, MD, discusses research with regional nodal irradiation in node-positive breast cancer.

Julia Whiteker, MSN, RN

Latest:

Julia Whiteker Describes the ONS Breast Care SIG

Julia Whiteker Describes the ONS Breast Care SIG Online Community

Julian Adams, PhD

Latest:

Dr. Adams on Tackling Storage and Logistical Challenges in Cell Therapy

Julian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.

Julian Kaye

Latest:

Dual Pathways Must Be Targeted in ER-Positive Breast Cancer

Treating estrogen receptorâ€“positive breast cancer without sparking resistance is a complex endeavor that should involve simultaneously targeting the hormone-signaling and PI3 kinase molecular pathways

Julie A. Kish, MD

Latest:

Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck Cancers

Researchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.

Julie A. Sosa, MD, MS

Latest:

Dr. Sosa on Risk Factors for Thyroid Cancer

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

Julie Cothren, DPh

Latest:

It's Time to Get Serious About New Rules for Handling Hazardous Drugs

Implementation of new standards for handling hazardous drugs in healthcare facilities is coming closer to reality now that the calendar has flipped to 2019.

Julie Djeu, PhD

Latest:

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Julie E. Bauman, MD

Latest:

Hedgehog Signal Inhibition Hope or Hype?

Once a human malignancy metastasizes, currently available cytotoxic chemotherapy is usually palliative. While conventional chemotherapy regimens are associated with objective tumor regression, this only occurs in a minority of patients.

Julie Graff, MD

Latest:

Dr. Graff Discusses the Treatment of Prostate Cancer

Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses the treatment of prostate cancer.